Contraindications of incretin therapy (revision 8)
Old revision·03:07, 2 Feb 2025·ResinRhoswen
| Contraindications of incretin therapy | |
|---|---|
| Absolute, labelled | Personal or family history of medullary thyroid carcinoma; MEN 2 |
| Also labelled | Prior hypersensitivity to the product |
| Cautions | Pancreatitis history, severe gastroparesis, pregnancy |
| Topic infobox · conventions | |
Contraindications of incretin therapy are the circumstances in which product labelling directs that a GLP-1 receptor agonist or dual agonist is not used. They differ in detail between products and jurisdictions, and this article describes the general pattern rather than any particular label.[1]
The labelled contraindications for the class are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and prior serious hypersensitivity to the product or an excipient. The first derives from rodent C-cell findings and is precautionary; see Adverse effects of GLP-1 receptor agonists.[2]
A larger set of cautions rather than contraindications covers pancreatitis history, severe pre-existing gastroparesis, pregnancy and breastfeeding, and combination with insulin or sulfonylureas. See Pregnancy and incretin therapy and Hypoglycaemia.[1]
Labelled contraindications
[edit]The thyroid contraindication is the distinctive one for this class. Rodent studies showed C-cell hyperplasia and tumours at high exposure; human C cells express the receptor at far lower density and no human signal has been established, but the contraindication is retained as a precaution.[2]
Hypersensitivity contraindications are ordinary for any injected peptide and cover both the active substance and excipients. Reactions specific to a formulation component do not necessarily extend to another product containing the same peptide.
Product labels also carry a substantial set of warnings that are not contraindications — pancreatitis, gallbladder disease, retinopathy in the context of rapid glycaemic improvement, and the perioperative considerations discussed at Aspiration risk under anaesthesia.[1]
Cautions and interactions
[edit]| Circumstance | Consideration |
|---|---|
| Concurrent insulin or sulfonylurea | Reduce the background agent; hypoglycaemia risk |
| Severe gastroparesis | Delayed emptying may worsen symptoms |
| Prior pancreatitis | Causality unestablished; caution conventional |
| Pregnancy or planning | Not recommended; weight loss undesirable in pregnancy |
| Severe renal impairment | Dehydration from vomiting can precipitate injury |
Renal considerations are indirect for most of this class: the peptides are not renally cleared to a degree requiring dose adjustment, but persistent vomiting and reduced intake can precipitate acute kidney injury in someone with limited reserve.[1]